FORT WORTH, Texas, April 21 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it has entered into an agreement with Quad Xenos Partners, LLC (QX Partners) to market and distribute their advanced wound care collagen product, CellerateRx(R) to federal government agencies. QX Partners is a Service Disabled Veteran Owned Small Business (SDVOB) that provides expertise and federally mandated leverage to small and mid-sized companies seeking to sell their products and services into the federal government. Their unique status and expertise in government affairs elevate their clients to the capability levels of their larger competitors for the long term. By law, a SDVOB must receive at least 3% of all government contracts and small/disadvantaged businesses warrant up to 20% of all government contracts. According to the Department of Veteran's Affairs (USAspending.gov) FY 2008, the VA spent over $5.5 billion on drugs, biologicals, and medical/surgical equipment and supplies. That did not include the potential for CellerateRx to be included into DOD medic kits, FEMA care packages, and other government agency purchases.
"We are excited about the opportunities presented by this relationship," said Cathy Bradshaw, President of Wound Care Innovations. "It will enable us to facilitate government sales in the many inpatient and outpatient VA centers around the country as well as the other government agencies." CellerateRx(R) is FDA cleared as a medical device and is indicated for all acute and chronic wounds except for 3rd degree burns.
"QX Partners is very pleased to team with Wound Care Innovations as this marks both companies' escalated engagement of the federal government-Veterans Administration hospitals in particular. We strongly believe that the combination of a Service Disabled Veteran Owned Small Business focused on selling the products of another small business is the best economic stimulus package possible," said QX Partners president, Alan B. McCain (LCDR, SC, USN, ret.) "VA doctors have long requested CellerateRx(R) to expedite wound care, and now they can buy it in greater quantities from fellow veterans."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.celleraterx.com.
About QX Partners, LLC:
QX Partners (www.qxpartners.com), a Service Disabled Veteran Owned Small Business based in Washington, DC, leverages our management consulting capabilities and excellent government agency knowledge to facilitate sales for small manufacturers and commodity producers across the nation. QXP specializes in aligning small businesses' products and services with the government agencies that need them most.
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information: Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Secretary 954-315-9242 817-820-7080
|SOURCE Wound Management Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved